Who is this study for: Patients with progressive, advanced, kinase inhibitor na�ve, RET-mutant medullary thyroid cancer
Status: Recruiting
Start Date: February 11, 2020
Intervention Type: Drug
Study Drugs: Vandetanib, Selpercatinib, Cabozantinib
Phase: Phase 3